Provided by Tiger Fintech (Singapore) Pte. Ltd.

LAEKNA-B

18.010
-0.300-1.64%
Volume:2.91M
Turnover:53.25M
Market Cap:7.38B
PE:-23.16
High:19.000
Open:18.290
Low:17.720
Close:18.310
52wk High:23.500
52wk Low:4.200
Shares:410.00M
HK Float Shares:410.00M
Volume Ratio:0.91
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.777
ROE:-34.59%
ROA:-19.92%
PB:9.47
PE(LYR):-23.16
PS:1459.56

Loading ...

Company Profile

Company Name:
LAEKNA-B
Exchange:
SEHK
Establishment Date:
2016
Employees:
84
Office Location:
3-2-467, 5 Xingbin Road,Lin Li Center,Sino-Italy Ningbo Ecological Park,Yuyao,Zhejiang Province,China
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.

Directors

Name
Position
LV Xiang Yang
Chairman of the Board,Executive Director,Chairman of the Nomination Committee
XIE Ling
Executive Director,Member of the Remuneration and Assessment Committee
GU Xiang Ju
Executive Director
YIN Xu Dong
Independent Director,Chairman of the Remuneration and Assessment Committee,Member of the Nomination Committee
LI Min
Independent Director,Member of the Nomination Committee,Member of the Audit Committee
ZHOU Jian
Independent Director,Member of the Remuneration and Assessment Committee,Chairman of the Audit Committee
David Guowei Wang
Director,Member of the Audit Committee
SUN Yuan
Director

Shareholders

Name
Position
LV Xiang Yang
CEO
WANG Li Qing
Vice General Manager
XIE Ling
Vice General Manager
CHAU Kwok Keung
CFO
KE Chen Yu
Corporate Secretary
HE Yong Ya
Corporate Secretary
GU Xiang Ju
Chief Science Officer